Evaluation of degarelix in the management of prostate cancer

Medical castration using gonadotropin-releasing hormone (GnRH) receptor agonists currently provides the mainstay of androgen deprivation therapy for prostate cancer. Although effective, these agents only reduce testosterone levels after a delay of 14 to 21 days; they also cause an initial surge in t...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Poppel, Hendrik
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004563/
https://www.ncbi.nlm.nih.gov/pubmed/21188095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004563/
https://www.ncbi.nlm.nih.gov/pubmed/21188095

Ejemplares similares